Evaxion biotech to present work on ai-immunology core technology at immuno uk 2021

Copenhagen, denmark, oct. 12, 2021 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today a presentation by emma christine jappe, phd, senior scientist, research & development, at the immuno uk conference being held in london on october 13-14, 2021.
EVAX Ratings Summary
EVAX Quant Ranking